Log In
BCIQ
Print this Print this
 

BioChaperone Lispro

Also known as: BioChaperone Ultra fast-acting insulin analog

  Manage Alerts
Collapse Summary General Information
Company Adocia S.A.
DescriptionUltra-fast acting formulation of insulin lispro using BioChaperone polymer technology
Molecular Target Insulin receptor (INSR)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat diabetes; Treat Type I and Type II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

$520.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/19/2014

Undisclosed

$50.0M

$520.0M

Get a free BioCentury trial today